Hikma Pharmaceuticals PLC (HIK) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

So good morning everyone and welcome to Hikma's 2026 interim results meeting with our CEO Said Darwazah and Acting CFO Areb KURDI and we also have Susan Ringdal and myself Guy Featherstone, Investor Relations. Before we start, I would like to remind you that any forward-looking statements or projections made by Hikma during this call are made in good faith, based on information currently available, and are subject to risks and uncertainties that may cause actual results to differ materially from those projected. For further information, please see the Principal Risks and Uncertainties section in Hikma's latest annual report. And with that, I'll hand over to Saeed for opening remarks before we head to Q&A. Thank you so much. So just quickly a few things to say. Obviously, so the results, sales are up. I think what's very exciting is that EBIT and EBITDA are up by almost 8%. EPS is up by 5%. And when we met last time, we said we had like four targets this year. One is to stabilize the business. And so we're talking about the injectable business. The other two businesses were doing well. and I think this has been achieved. We talked about making the company more agile, quicker decision making and we have taken tons of decisions and now the way the company is structured I think very much supports this quick decision making. It supports the senior management of the team to take quick decisions and to take quick actions and reactions where they are needed. We said we will invest for the future. We have done a lot of investment in people, I think is most important, in talent and people. We have done investment in equipment. And of course, R&D spend, as you can see, is up. So we are really setting up the company for the future. So we hope that, again, we feel extremely comfo...